The treatment modalities in the field of acute leukemia have seen spectacular changes in recent years. The introduction of chimeric antigen receptor T-cells (CAR T-cells) and bispecific T-cell engagers (BiTEs) dramatically improved the outcome of heavily pretreated patients with B-cell acute lymphoblastic leukemia (B-ALL). For the treatment of acute myeloid leukemia (AML), immunotherapy is more difficult to design, but also in this setting progress has been made. This text will describe recent advances in the field of acute leukemia presented at the latest EHA meeting.

(BELG J HEMATOL 2018;9(4):148–51)